Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 41Carcinoma, Non-Small-Cell Lung 35Neoplasm Metastasis 32Pancreatic Neoplasms 30Prostatic Neoplasms 24Lung Neoplasms 21Carcinoma, Hepatocellular 21Melanoma 16Breast Neoplasms 12Liver Neoplasms 10Glioblastoma 10Squamous Cell Carcinoma of Head and Neck 8Carcinoma, Renal Cell 8Neoplasms 7Head and Neck Neoplasms 7Kidney Neoplasms 6Gliosarcoma 6Sarcoma 5Glioma 5Central Nervous System Neoplasms 5Uterine Cervical Neoplasms 4Salivary Gland Neoplasms 4Colorectal Neoplasms 4Vulvar Neoplasms 3Vaginal Neoplasms 3Recurrence 3Radiation Injuries 3Pain 3Ovarian Neoplasms 3Fallopian Tube Neoplasms 3

Interventions

enzalutamide 2radium Ra 223 dichloride 1poly ICLC 1olaparib 1fluciclovine F-18 1cabazitaxel 1bempegaldesleukin 1afuresertib 1Radiosurgery 1Radionuclide Imaging 1Prednisone 1Nivolumab 1Docetaxel 1Clinical Trials, Phase I as Topic 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-resistant Prostate Cancer × Radiosurgery × Clear all
NCT03835533 2024-04-12

PORTER

Parker Institute for Cancer Immunotherapy

Phase 1 Completed
43 enrolled 19 charts
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡